GLP-1 drugs linked to higher osteoporosis risk in new research

14 articles · Updated · WBRZ · Apr 28

A Baton Rouge study finds GLP-1 weight loss medications may raise osteoporosis risk by up to 30%, likely due to rapid weight loss and nutritional deficiencies.
Angela Roy of Baton Rouge General Hospital highlights that reduced protein, calcium, and vitamin D intake, along with muscle loss, may accelerate bone weakening in patients using GLP-1s.
Osteoporosis, a leading cause of disability in older women, can result in serious fractures. Experts recommend strength training and nutritional monitoring for those taking GLP-1 drugs to protect bone health.

With GLP-1s causing muscle loss, how can you lose weight without sacrificing your skeleton?

Are doctors adequately warning patients about the hidden skeletal costs of rapid weight loss?

Why might a drug mimicking a bone-protective hormone paradoxically increase fracture risk?

Should a bone density scan be mandatory before anyone starts taking Wegovy or Zepbound?

Could combining weight loss drugs with strength training become the new medical standard?